Cargando…
Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
OBJECTIVES: The TITAN study is a randomized, double‐blind, placebo‐controlled, multinational trial that evaluated apalutamide with androgen deprivation therapy in patients with metastatic castration‐sensitive prostate cancer. At the first interim analysis in the Japanese subpopulation (median follow...
Autores principales: | Uemura, Hirotsugu, Arai, Gaku, Uemura, Hiroji, Suzuki, Hiroyoshi, Aoyama, Junya, Hatayama, Tomoyoshi, Ito, Miku, Lefresne, Florence, McCarthy, Sharon, Mundle, Suneel, He, Jin, Chi, Kim N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310605/ https://www.ncbi.nlm.nih.gov/pubmed/35293030 http://dx.doi.org/10.1111/iju.14843 |
Ejemplares similares
-
Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
por: Chung, Byung Ha, et al.
Publicado: (2021) -
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020) -
Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
por: Uemura, Hiroji, et al.
Publicado: (2020) -
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019) -
Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Zang, Zhijiang, et al.
Publicado: (2022)